Renuen Corp RENU
Despite bearing the “Caveat Emptor” label on OTC Markets, RENU is currently rocking, and also receiving a “Strong Buy” Rating at BARCHART.
There have been no public statements issued by the company since its symbol-change (formerly SHKZ) back in February, and yet the stock is garnering an awful lot of attention, as activity and PPS have surged of late.
In total, a possible gain of 338% exisited with RENU in the past six sessions, with yesterday’s dollar-volume coming to six figures.
Arena Pharmaceuticals, Inc. ARNA
ARNA is a stock that we wanted to add to our longer-term radar this morning. The company recently received positive recommendations from an FDA advisory panel for its drug which treats obesity.
We want to watch this play carefully heading into the month of June, being the target month for FDA approval, as we believe that there could be trading opportunities in the meantime.
IDOI, EMWW, FROI, ZNGA (Bottom!!!)